K-LARS trial: protocol for a multicentre randomised controlled trial evaluating a knowledge-enhanced digital intervention to prevent low anterior resection syndrome in Korea Authors: Seung-Bum Ryoo, Hong-Min Ahn, Byung-Ho Nam, Young Min Song, Dae Kyung Sohn Published: 2025 ABSTRACT AbstractIntroductionLow anterior resection syndrome (LARS) is a common functional complication after sphincter-preserving surgery for rectal cancer that significantly impairs the quality of life. Current postoperative management strategies are suboptimal, and effective preventive approaches are lacking. This study aims to evaluate the impact of a mobile-based, knowledge-enhanced digital intervention for reducing the incidence of major LARS.SettingThis is a multicentre, open-label, parallel-group, randomised controlled trial to be conducted across three academic medical centres in Korea.Methods and analysisA total of 300 adult patients who underwent low anterior resection or stoma reversal after rectal cancer surgery will be randomly assigned in a 1:1 ratio to the intervention group (mobile digital programme) or the control group (standard educational materials). The digital programme includes daily symptom monitoring, exercise suggestions, dietary recommendations and structured feedback from healthcare providers during clinical visits based on outcomes. The primary outcome is the incidence of major LARS (score ≥30) at 12 months postoperatively. Secondary outcomes include longitudinal changes in LARS score, quality of life (European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core 30 (C30), EORTC QLQ-Colorectal Cancer 29 (CR29)), European Quality of Life 5 Dimensions Level Version (EQ-5D-5L), patient satisfaction and programme adherence. Statistical analyses will include stratified chi-squared tests and mixed-effects models based on the intention-to-treat principle.Ethics and disseminationThe trial received ethical approval from the Institutional Review Board of the National Cancer Centre, Korea. Written informed consent will be obtained from all participants. The findings will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberNCT07041515.Keywords: Quality of Life, Mobile Applications, Colorectal surgery STRENGTHS AND LIMITATIONS OF THIS STUDY This multicentre randomised controlled trial will evaluate a digital intervention using a rigorous methodology across three academic medical centres. This multicentre randomised controlled trial will evaluate a digital intervention using a rigorous methodology across three academic medical centres. The intervention will include structured clinician feedback rather than passive digital monitoring, enhancing its real-world applicability. The intervention will include structured clinician feedback rather than passive digital monitoring, enhancing its real-world applicability. The study incorporates a feasibility phase to assess usability and inform refinements to the digital platform prior to full-scale evaluation. The study incorporates a feasibility phase to assess usability and inform refinements to the digital platform prior to full-scale evaluation. Longitudinal outcomes will be measured at multiple postoperative time points to assess both short- and long-term effects. Longitudinal outcomes will be measured at multiple postoperative time points to assess both short- and long-term effects. As an open-label design, participant and provider blinding is not possible, but outcome assessors and data analysts will remain blinded to minimise assessment bias. As an open-label design, participant and provider blinding is not possible, but outcome assessors and data analysts will remain blinded to minimise assessment bias. Introduction Low anterior resection syndrome (LARS) is a constellation of bowel dysfunction symptoms that frequently occurs in patients who undergo sphincter-preserving surgery for rectal cancer. Symptoms such as faecal urgency, clustering, incontinence and erratic bowel frequency may persist long after surgery, substantially diminishing patients’ health-related quality of life (HRQoL).1,3 The LARS score, developed by Emmertsen and Laurberg, has been validated as a robust tool to quantify the severity of this syndrome and classify it as no, minor or major.4 Major LARS is associated with poor psychosocial outcomes, dietary restrictions and impaired return to social and occupational functions.2 3 The increasing use of total mesorectal excision, preoperative chemoradiotherapy and anastomosis preservation techniques has led to improved oncologic outcomes; however, functional sequelae such as LARS remain under-addressed in routine postoperative care.5 6 Although dietary modifications, pelvic floor rehabilitation, pharmacological agents and transanal irrigation have been proposed, there is currently no standardised and scalable approach to prevent or mitigate LARS early in the postoperative period.7 8 In addition, pelvic floor muscle training,9 transanal irrigation10 and structured patient counselling11 12 have shown promise in improving functional outcomes and addressing the unmet needs of patients with major LARS. Digital health interventions have emerged as promising tools to enhance chronic disease management by supporting patient self-efficacy, monitoring symptom trajectories and providing real-time feedback. For colorectal cancer survivors, mobile health (mHealth) platforms offer an accessible and cost-effective medium for promoting bowel health education, behavioural modifications and timely symptom reporting.13 14 Several pilot studies, including interactive web-based and peer-supported platforms for the LARS, have demonstrated the feasibility of technology-assisted symptom management in survivors of rectal cancer.15 Predictive tools such as the POLARS score have also been proposed to assess the risk of postoperative bowel dysfunction and guide tailored interventions.16 Despite these advances, randomised trials evaluating digital physiotherapy and behavioural interventions remain limited, as highlighted by the PARiS and POLARiS protocols.17 18 Recent evidence supports the use of patient-centred digital education platforms and behavioural interventions, such as pelvic floor training and web-assisted rehabilitation tools, to improve mental health and functional outcomes in LARS.14 19 Korean-specific tools, including validated translations of the LARS score, have further improved the ability to localise assessment and support strategies.20 21 Building on these developments, the knowledge-enhanced digital intervention to prevent low anterior resection syndrome (K-LARS) intervention incorporates daily symptom self-monitoring with context-aware guidance on diet, pelvic floor exercises and self-care strategies, complemented with clinician reinforcement provided during scheduled outpatient visits or when clinically indicated. This mechanism is intended to enhance self-efficacy and support adaptive bowel habit formation. The K-LARS trial was designed to address gaps in the management of LARS. This multicentre randomised controlled trial (RCT) aims to evaluate the impact of a knowledge-enhanced digital intervention aimed at reducing the incidence of major LARS after rectal cancer. By implementing a mobile-based support programme in the early postoperative period, this trial seeks to evaluate whether it can mitigate functional deterioration, support proactive symptom management and improve long-term quality of life among rectal cancer survivors. Specifically, the study has four prespecified objectives: To compare the incidence of major LARS between intervention and control groups at 12 months postoperatively (primary endpoint) To compare the incidence of major LARS between intervention and control groups at 12 months postoperatively (primary endpoint) To evaluate longitudinal changes in LARS symptoms using the LARS score at baseline and at 3, 6, 12, 24, 36 and 60 months To evaluate longitudinal changes in LARS symptoms using the LARS score at baseline and at 3, 6, 12, 24, 36 and 60 months To assess changes in HRQoL using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core 30 (C30), EORTC QLQ- Colorectal Cancer 29 (CR29) and European Quality of Life 5 Dimensions Level Version (EQ-5D-5L) at baseline and at 6, 12, 24, 36 and 60 months To assess changes in HRQoL using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Core 30 (C30), EORTC QLQ- Colorectal Cancer 29 (CR29) and European Quality of Life 5 Dimensions Level Version (EQ-5D-5L) at baseline and at 6, 12, 24, 36 and 60 months To evaluate patient adherence and engagement with the K-LARS intervention and explore associations with clinical outcomes during follow-up To evaluate patient adherence and engagement with the K-LARS intervention and explore associations with clinical outcomes during follow-up Methods and analysis Study design This is a two-phase, multicentre, open-label, parallel-group RCT. The first phase is a single-arm feasibility study involving 20 participants, conducted with a separate group before starting the main RCT. The first phase will run from 15 November 2025 to February 2026 (approximately 3 months). The objective of this phase is to evaluate the usability of the mobile-based intervention, assess the patterns of engagement and adherence and identify any practical or technical barriers to sustained real-world use. Insights from this phase will guide refinements to the digital platform before launching the main trial. These refinements may include minor adjustments to user interface clarity, notification timing or onboarding flow, with the aim of enhancing usability and optimising participant interaction with the system. Usability will be assessed using the System Usability Scale, complemented by brief structured interviews guided by a predefined questionnaire (online supplemental file 1) to explore barriers and facilitators to navigation, comprehension and sustained engagement. Patterns of app engagement and data entry will be analysed descriptively to identify points of early disengagement or reduced activity, while data completeness will be evaluated based on the consistency and quality of responses across symptom monitoring, dietary input and exercise tracking modules. This pilot phase is intended to inform protocol and intervention adjustments prior to the commencement of the full randomised trial and will not involve the assessment of clinical outcomes. In the second phase, 300 participants will be enrolled in the full-scale RCT, consistent with the trial registration (NCT07041515). The full-scale randomised trial is scheduled to begin on 15 February 2026, with recruitment continuing through December 2027 and final follow-up completed by December 2030. New eligible participants who were not included in the first phase will be enrolled and randomised in a 1:1 ratio to either the intervention or control group. Randomisation will be stratified by institution using a computerised block randomisation scheme to ensure balanced allocation across sites. Due to the nature of the intervention, blinding of participants and care providers will not be feasible; however, outcome assessors and data analysts will remain blinded to the group allocation. Figure 1 shows a flow chart of the study design. Study design of the K-LARS trial. LARS, low anterior resection syndrome; QoL, quality of life; RCT, randomised controlled trial. The study will follow-up the participants for 60 months postoperatively, with a primary endpoint assessment at 12 months. Follow-up assessments will be conducted at 1, 3, 6, 12, 24, 36 and 60 months to evaluate the short- and long-term effects of the intervention. A data monitoring committee composed of independent experts will oversee trial conduct, monitor safety and ensure protocol compliance throughout the study period. Study setting and randomisation This multicentre prospective clinical trial will be conducted across three academic medical centres in Korea, each with specialist colorectal surgery capability and institutional infrastructure to support prospective clinical trials. Participating institutions were selected based on their academic status and proven experience in conducting investigator-initiated trials under Institutional Review Board (IRB) oversight. Participants will be randomly assigned using computer-generated block randomisation (block size=4), stratified by (1) participating hospital and (2) whether the patient has a diverting ileostomy at baseline. The allocation sequence will be centrally managed and revealed only after patient enrolment via a secure web-based randomisation system to ensure allocation concealment. Although this is an open-label trial, outcome assessors and data analysts will remain blinded to group allocation throughout the study. Participants Participants will be recruited from patients scheduled to undergo sphincter-preserving rectal cancer surgery or those scheduled for stoma reversal. Detailed criteria have been established to ensure appropriate patient selection and study compliance. Inclusion criteria: Adults aged 20–70 years Adults aged 20–70 years Histologically confirmed rectal cancer with a tumour located within 15 cm of the anal verge, with patients requiring or having undergone sphincter-preserving surgery or scheduled for stoma reversal (for patients undergoing stoma reversal, stoma closure must be scheduled within 12 months after rectal surgery). Histologically confirmed rectal cancer with a tumour located within 15 cm of the anal verge, with patients requiring or having undergone sphincter-preserving surgery or scheduled for stoma reversal (for patients undergoing stoma reversal, stoma closure must be scheduled within 12 months after rectal surgery). Estimated survival time of more than 1 year Estimated survival time of more than 1 year Ownership and usage capability of a smartphone application (by patient or main caregiver) Ownership and usage capability of a smartphone application (by patient or main caregiver) Capability to understand their condition and provide written informed consent Capability to understand their condition and provide written informed consent Exclusion criteria: Undergoing chemotherapy or radiotherapy at the time of consent Undergoing chemotherapy or radiotherapy at the time of consent Scheduled for extensive colectomy beyond rectal resection (eg, subtotal or total colectomy) Scheduled for extensive colectomy beyond rectal resection (eg, subtotal or total colectomy) Inability to be reached via telephone Inability to be reached via telephone Inability to read or comprehend the Korean language Inability to read or comprehend the Korean language Unable to provide valid informed consent due to cognitive or medical conditions Unable to provide valid informed consent due to cognitive or medical conditions Withdrawal criteria: Participant withdraws consent Participant withdraws consent Inability to complete follow-up over a minimum period of 12 months Inability to complete follow-up over a minimum period of 12 months Investigator determines discontinuation due to clinical or protocol-related concerns Investigator determines discontinuation due to clinical or protocol-related concerns Potential participants will be identified during the pre- and perioperative periods at each participating site. Eligibility screening will include a review of medical records and direct interviews. Informed consent will be obtained from trained research staff. Baseline variables and data sources Baseline demographic and clinical variables will be collected from each institution’s electronic medical records, including: Age, sex and body mass index Age, sex and body mass index Comorbidities (eg, diabetes, cardiovascular disease and prior abdominal surgery) Comorbidities (eg, diabetes, cardiovascular disease and prior abdominal surgery) Tumour location and clinical stage Tumour location and clinical stage Type of surgery and anastomosis (eg, low anterior resection or intersphincteric resection and stapled vs hand-sewn) Type of surgery and anastomosis (eg, low anterior resection or intersphincteric resection and stapled vs hand-sewn) Receipt and timing of neoadjuvant/adjuvant therapy Receipt and timing of neoadjuvant/adjuvant therapy Time interval from primary surgery to stoma closure (if applicable) Time interval from primary surgery to stoma closure (if applicable) Baseline bowel function prior to randomisation Baseline bowel function prior to randomisation Patient-reported variables will be collected differently between groups: Intervention group: symptom burden, LARS score and HRQoL will be collected via the K-LARS mobile application. Intervention group: symptom burden, LARS score and HRQoL will be collected via the K-LARS mobile application. Control group: the same variables will be collected using paper-based questionnaires. Control group: the same variables will be collected using paper-based questionnaires. The specific assessment time points for each variable are presented in table 1. Table 1Schedule of outcome measurementOutcomeBaseline1 month3 months6 months12 months24 months36 months60 monthsPrimary outcomeLARS score 1 year after surgeryXSecondary outcomesEORTC QLQ-C30XXXXXXEORTC QLQ-CR29XXXXXXEQ-5D-LXXXXXXLARS scoreXXXXXXXXAwareness and satisfaction questionnaireXXEORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30; EORTC QLQ-CR29, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire- Colorectal Cancer 29; EQ-5D-L, European Quality of Life 5 Dimensions Level Version; LARS score, low anterior resection syndrome score. Schedule of outcome measurement EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30; EORTC QLQ-CR29, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire- Colorectal Cancer 29; EQ-5D-L, European Quality of Life 5 Dimensions Level Version; LARS score, low anterior resection syndrome score. Intervention group management Participants in the intervention arm will receive access to a mobile application specifically designed for postoperative LARS prevention. At the time of enrolment, a trained research coordinator nurse will assist the patient in installing the mobile application and provide a structured onboarding session (approximately 20 min). During this guided session, the patient will receive step-by-step instructions on daily symptom logging, educational content navigation and exercise module usage. Patients will complete the baseline patient-reported assessments directly within the app and will be explicitly instructed to use the app on a daily basis as part of the study protocol. The application comprises the following modules (figure 2): User interface of the LARS Care mobile application: (A) Personalised pelvic floor muscle exercise module; (B) customised meal planning feature; (C) bowel movement logging screen; (D) dietary intake log; (E) Low Anterior Resection Syndrome (LARS) score input and the EuroQol 5-Dimension (EQ-5D) health-related quality of life survey; and (F) medication tracking module. Symptom monitoring: Patients will record their daily bowel function, urgency and continence status. In addition, the app sends weekly notifications prompting patients to input their LARS scores. All data are visualised and periodically reviewed by clinical staff. Symptom monitoring: Patients will record their daily bowel function, urgency and continence status. In addition, the app sends weekly notifications prompting patients to input their LARS scores. All data are visualised and periodically reviewed by clinical staff. Tailored education: Based on initial and ongoing assessments, patients will receive targeted educational content related to LARS, including dietary recommendations and pelvic floor muscle guidance. Tailored education: Based on initial and ongoing assessments, patients will receive targeted educational content related to LARS, including dietary recommendations and pelvic floor muscle guidance. Exercise recommendations: Guided video sessions will provide pelvic floor muscle training and relaxation techniques. Exercise recommendations: Guided video sessions will provide pelvic floor muscle training and relaxation techniques. Dietary suggestions: Personalised dietary recommendations will be offered to improve stool consistency and alleviate symptoms. Dietary suggestions: Personalised dietary recommendations will be offered to improve stool consistency and alleviate symptoms. Feedback from healthcare providers: Through in-app communication tools, such as messaging with assigned nurse coordinators, patients will receive feedback during scheduled outpatient visits based on symptom trends and outcomes. Clinical staff periodically review dashboard-aggregated symptom reports and may provide earlier intervention if clinically indicated. Standardised escalation criteria and unified response templates are used across all sites to ensure consistency while preserving appropriate clinical discretion. Feedback from healthcare providers: Through in-app communication tools, such as messaging with assigned nurse coordinators, patients will receive feedback during scheduled outpatient visits based on symptom trends and outcomes. Clinical staff periodically review dashboard-aggregated symptom reports and may provide earlier intervention if clinically indicated. Standardised escalation criteria and unified response templates are used across all sites to ensure consistency while preserving appropriate clinical discretion. Control group management The control group will receive standardised educational materials in pamphlet form consistent with the current postoperative care guidelines. These include: Basic bowel management instructions Basic bowel management instructions General advice on hydration, fibre intake and physical activity General advice on hydration, fibre intake and physical activity Self-monitoring logs (paper-based) Self-monitoring logs (paper-based) No interactive features or active digital follow-up; however, patients will be routinely asked about their symptoms and provided guidance during scheduled outpatient clinic visits. No interactive features or active digital follow-up; however, patients will be routinely asked about their symptoms and provided guidance during scheduled outpatient clinic visits. Patient and public involvement None. Outcomes and measures Primary outcome The primary endpoint is the proportion of patients developing major LARS (score ≥30) at 12 months postoperatively, measured using the validated LARS score. The LARS score consists of five questions addressing incontinence, urgency, clustering and frequency of bowel movements, with total scores categorised as no LARS (0–20), minor LARS (21–29) and major LARS (≥30). Secondary outcomes QoL, measured using the EORTC QLQ-C30 and CR29 modules. The statistical endpoint will be the mean change from baseline to each follow-up point. Higher global scores reflect better QoL, and higher symptom scores reflect greater symptom burden. QoL, measured using the EORTC QLQ-C30 and CR29 modules. The statistical endpoint will be the mean change from baseline to each follow-up point. Higher global scores reflect better QoL, and higher symptom scores reflect greater symptom burden. Generic health status, assessed using EQ-5D-5L. The index and visual analogue scale scores will be analysed as mean changes from baseline. Generic health status, assessed using EQ-5D-5L. The index and visual analogue scale scores will be analysed as mean changes from baseline. Patient satisfaction will be assessed using a structured, study-specific usability and acceptability survey (provided as online supplemental material 1), designed to evaluate perceived usefulness, ease of use, self-management support and overall recommendation intention. Patient satisfaction will be assessed using a structured, study-specific usability and acceptability survey (provided as online supplemental material 1), designed to evaluate perceived usefulness, ease of use, self-management support and overall recommendation intention. Symptom changes: Repeated measures of the LARS score will be collected at 1, 3, 6, 12, 24, 36 and 60 months. Symptom changes: Repeated measures of the LARS score will be collected at 1, 3, 6, 12, 24, 36 and 60 months. App usage monitoring: App adherence will be quantified as the percentage of prescribed daily symptom logs completed during the 12-week intervention period (primary adherence) and the proportion of exercise modules completed (secondary adherence). Engagement will include weekly log-in frequency, completion of education modules and the number of weeks during which adherence targets are met; these will be analysed in relation to clinical outcomes. App usage monitoring: App adherence will be quantified as the percentage of prescribed daily symptom logs completed during the 12-week intervention period (primary adherence) and the proportion of exercise modules completed (secondary adherence). Engagement will include weekly log-in frequency, completion of education modules and the number of weeks during which adherence targets are met; these will be analysed in relation to clinical outcomes. Sample size In the first phase, a pilot study is planned to be conducted with 20 patients to assess the feasibility of the app. The second phase RCT will not include patients from the first phase pilot study, and the sample size was set as follows. The sample size calculation was based on the primary endpoint: the proportion of patients developing major LARS (LARS score ≥30) at 12 months postoperatively. According to a previous study,1 approximately 44% of patients undergoing low anterior resection developed major LARS. The assumption of a 29% absolute risk reduction, corresponding to a relative risk (RR) reduction of 34% (RR=0.66), was informed by published data from prospective trials evaluating pelvic floor rehabilitation and multimodal supportive interventions for LARS. These trials reported RR reductions of approximately 30%–40% at 12 months postoperatively.3 9 Accordingly, a 29% reduction was selected as a conservative yet clinically meaningful effect size for this trial. Assuming a one-sided significance level (alpha) of 0.05 and a statistical power of 80% (beta=0.20), we used a chi-square test for two proportions to determine the required sample size. Under these assumptions, 129 participants will be required for each group. To account for an anticipated dropout rate of 15%, we increased the target sample size to 150 participants per group, totalling 300 participants. This calculation ensures that the study will have sufficient power to detect clinically meaningful differences in the primary outcome between the intervention and control groups. Statistical analysis The primary outcome, the proportion of patients developing major LARS at 12 months postoperatively, will be analysed using the Mantel–Haenszel chi-square test, stratified by study site, to control for potential institutional variation. Site-adjusted RRs and 95% CIs will be calculated using the Mantel–Haenszel method. For each site, 2×2 contingency tables will be constructed, and the pooled RR will be derived as a weighted average of site-specific estimates. CIs will be computed on the log scale and back-transformed for presentation. All analyses will be performed using standard statistical software R (v4.4.0; R Foundation for Statistical Computing, Vienna, Austria), which will be used to compute Mantel–Haenszel RRs, 95% CIs and associated p values. A sensitivity analysis using a logistic regression model adjusted for potential confounders (eg, age, sex, type of surgery and baseline bowel function) will be conducted. Secondary outcomes, including QoL scores (EORTC QLQ-C30, CR29), EQ-5D-5L indices and patient satisfaction ratings, will be analysed using repeated-measures analysis of variance (ANOVA) or mixed-effects linear regression models, with time as a within-subject factor and group as a between-subject factor. These methods account for intraindividual correlations across repeated measures and allow for the estimation of group-by-time interaction effects. Non-normally distributed data analysed using non-parametric methods (eg, the Wilcoxon rank-sum test) will be employed. Longitudinal LARS score changes will be analysed using linear mixed-effects models, which inherently account for missing observations under the missing-at-random assumption. Multiple imputation will be conducted only as a sensitivity analysis to assess the robustness of findings. Programme adherence and engagement metrics will be summarised descriptively and examined for correlations with clinical outcomes using Spearman’s rho test. All the analyses will follow the intention-to-treat principle. Per-protocol analyses will be conducted as secondary sensitivity analyses to explore the robustness of the intervention effects. These approaches are consistent with those of prior LARS trials, enabling comparability and methodological rigour.7 18 Ethics and dissemination This study has been reviewed and approved by the IRB of the National Cancer Centre, Korea (IRB No. NCC2025-0022). Written informed consent (online supplemental material 2) will be obtained from all participants before enrolment. Participant confidentiality will be strictly protected, and all data will be pseudonymised and securely stored on encrypted servers accessible only to authorised personnel. Ethical considerations include minimal risk from digital intervention with specific monitoring of digital fatigue, technology-related anxiety and loss of privacy. Any adverse effects, including those related to app overuse or unintended consequences of self-monitoring, will be documented and managed according to the institutional policy. Auditing of trial conduct will not be routinely conducted but may be performed by institutional quality assurance teams if necessary. Access to the final dataset will be limited to the principal investigator and approved statisticians. This study complied with the principles of the Declaration of Helsinki and Good Clinical Practice. Protocol amendments will be reported to the IRB and trial registry. The findings of this trial will be disseminated through: Publication in peer-reviewed international journals Publication in peer-reviewed international journals Presentations at national and international scientific conferences Presentations at national and international scientific conferences Reports to institutional stakeholders and healthcare policy bodies Reports to institutional stakeholders and healthcare policy bodies Additionally, a summary of the study findings will be shared with participants on request. If digital intervention proves beneficial, efforts will be made to scale up the programme for broader clinical implementation. Supplementary material Acknowledgements This research was supported by a grant from the Korean Cancer Survivors Healthcare R&D Project through the National Cancer Center funded by the Ministry of Health & Welfare, Republic of Korea (grant no. RS-2023-CC140143). Footnotes Funding: This research was supported by a grant from the Korean Cancer Survivors Healthcare R&D Project through the National Cancer Center, funded by the Ministry of Health & Welfare, Republic of Korea (grant no. RS-2023-CC140143). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-107819). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. References Supplementary Materials